



# Curriculum vitae

---

## *Contact information*

Kimmo Porkka  
Helsinki University Hospital Comprehensive Cancer Center  
Department of Hematology  
P.O. Box 372, 00029 HUCH, Helsinki, FINLAND  
kimmo.porkka@helsinki.fi  
+358-9-471-72338 (tel)  
+358-50-427-0192 (mobile phone)  
+358-9-471-72351 (fax)

## *Current clinical position*

Head of department of hematology  
Helsinki University Hospital Comprehensive Cancer Center  
Helsinki, FINLAND

## *Current academic position*

Professor of clinical hematology (part-time)  
University of Helsinki  
Hematology Research Unit Helsinki  
P.O. Box 700, 00029 HUCH, Helsinki, FINLAND

## *Education*

Licentiate in Medicine (M.D.), 1983-1989, University of Turku,  
Finland  
Doctor of Medical Sciences (Ph.D.), 1987-1991, University of  
Turku, Finland  
Docent in Experimental Internal Medicine, 1991-1995, University of  
Helsinki, Finland  
Specialist in General Internal Medicine, 1993-1997, University of  
Helsinki, Finland  
Specialist in Clinical Hematology, May 1997-1999, University of  
Helsinki, Finland

### *Professional employment*

Assistant in physiology, University of Turku, 1988  
General medical practitioner 1989-1990  
Registrar, Department of Oncology, University of Helsinki, 1990-1992  
Registrar, Internal Medicine, Department of Internal Medicine, University of Helsinki, 1992-1996  
Registrar, Clinical Hematology, Helsinki University Central Hospital, Department of Medicine, Division of Hematology, Helsinki, Finland, 1997-1999  
Specialist in clinical hematology, Helsinki University Central Hospital, Department of Medicine, Division of Hematology, Helsinki, Finland, 2001-  
Principal investigator, Hematology Research Unit (HRU), Biomedicum Helsinki  
Professor of Clinical Hematology, University of Helsinki, 2008-  
Head of Division, Helsinki University Central Hospital, Department of Medicine, Division of Hematology, Helsinki, Finland, 2008-

### *Research interest*

Molecularly targeted therapy and immunotherapy of hematological malignancies

### *Research experience*

Clinical epidemiology, Department of Medicine, University of Turku, Finland, 1986-1991  
Clinical breast cancer research, Department of Oncology, University of Helsinki, Finland, 1991-1992  
Human molecular genetics; genetic mapping of complex diseases, Department of Medicine, Division of Endocrinology, University of Helsinki and National Public Health Institute, Departments of Biochemistry and Human Molecular Genetics, 1993-1998  
Post-doctoral fellow, basic and applied cancer research, The Burnham Institute, La Jolla, USA, 1999-2001  
Characterization of leukemia-specific proteins and ligands, 2001-  
Phase II-III clinical studies (academic and company-sponsored) on chronic myeloid leukemia and Ph-positive ALL, 2003-  
Immunomodulatory effects of tyrosine kinase inhibitors 2007-  
Personalized therapy for acute leukemia 2010-

### *Thesis supervision*

Dr. Ilpo Nuotio, University of Turku, Finland, 1994-1999  
M.Sc. Tuija Lundán, University of Helsinki, Finland, 2003-2008  
Dr. Franz Gruber, University of Tromso, Norway, 2004-2009  
M.Sc. Sari Hernesniemi, University of Helsinki, Finland, 2007-2012  
M.Sc. Anna Kreutzman, University of Helsinki, Finland, 2008-2012  
Dr. Peter Rohon, University of Helsinki, Finland, and University of Olomouc, 2007-  
Dr. Perttu Koskenvesa, University of Helsinki, Finland, 2007-  
Dr. Hanna Koskela, University of Helsinki, Finland, 2009-  
Dr. Mika Kontro, University of Helsinki, Finland, 2010-  
Paavo Pietarinen, University of Helsinki, Finland, 2012-

### *Main collaborators*

Prof. Olli Kallioniemi, FIMM, University of Helsinki (personalized medicine of acute leukemia)  
Prof. Satu Mustjoki, Hematology Research Unit Helsinki, University of Helsinki (immunotherapy of leukemia)  
Bristol-Myers Squibb, Celgene, Novartis, Pfizer (Phase I-III drug studies, basic research)

### *Good clinical practice qualification*

Fully qualified for running Phase I-III clinical drug studies based on onsite and offsite training in relation to several clinical drug studies and investigator meetings (BMS, Celgene, Merck, Novartis, Pfizer). Date of last training: 26-SEPT-2014 (web-training, Pfizer, Inc.)

### *Major Fellowships and grants*

UICC ACSBI 1999-2000  
Finnish Medical Foundation 2001-2004  
Gyllenberg Foundation, Helsinki 2001-2005, 2008-2009  
Finnish Cancer Organizations 2006-2008  
A special governmental grant for health sciences and research (HUCH EVO) 2002-2008

## *Patents*

- Porkka K. (inventor), Ruoslahti E. "Hmgn2 Peptides And Related Molecules That Selectively Home To Tumor Blood Vessels And Tumor Cells." United States Patent Application Docket P-LJ 5234, 2003
- Laakkonen P., Porkka K. (co-inventor), Ruoslahti E. "Peptides that Home to Tumor Lymphatic Vasculature and Methods of Using Same". United States Patent Application No.: 10/290,385, 2002.
- BMS, Porkka K (co-inventor): "Combinations, methods and compositions for treating cancer". Provisional United States Patent Application No.: 10729 PSP, 2006

## *Publications*

- 103 original publications and 6 review articles in international peer reviewed journals
- 15 articles in Finnish medical journals
- Several abstracts in international meetings

## *Research home page*

<http://www.helsinki.fi/hematology/>

Last updated: February 8, 2015



---

Kimmo Porkka